摘要
目的观察依达拉奉联合纤溶酶治疗急性脑梗死的临床疗效。方法将急性脑梗死患者80例随机分为2组:治疗组40例,依达拉奉注射液30mg加生理盐水100mL静脉滴注,每日2次,联合纤溶酶注射液首日100U加5%葡萄糖注射液250mL静脉滴注,第2天起200U加5%葡萄糖注射液250mL静脉滴注,共14d;对照组40例,单用纤溶酶,剂量及用法同治疗组。治疗前后监测神经功能缺损评分。结果 2组治疗后7、14、30、90d神经功能缺损评分、日常生活活动能力指数治疗组均优于对照组,差异有统计学意义(P<0.05),治疗前组间差异无统计学意义(P>0.05)。结论依达拉奉联合纤溶酶治疗急性脑梗死疗效显著。
Objective To observe the clinical effect of edaravone combined with fibrinolysin for treating acute cerebral infarc-tion .Methods 80 cases of acute cerebral infarction were randomly divided into the two groups .The treatment group（40 cases） was treated by edaravone injection 30mg plus normal saline 100 mL by intravenous drip ,twice daily ,fibrinolysin injection 100 U plus 5%glucose injection 250 mL by intravenous drip on 1 d ,subsequently 200U plus 5% glucose 250 mL by intravenous drip from the next day ,for 14 d;the control group（40 cases ） used fibrinolysin alone ,the dose and usage were same to the treatment group .The neuro-logical impairment scale scores（NIHSS） were monitored before and after treatment in the two groups .Results The NIHSS scores and Barthel index on 7 ,14 ,30 ,90 d after treatment in the treatment group were superior to those in the control group （P〈0 .05） ,no statistical difference before treatment between the two group existed .Conclusion Edaravone combined with fibrinolysin has better effect for treating acute cerebral infarction .
出处
《重庆医学》
CAS
CSCD
北大核心
2013年第27期3262-3263,共2页
Chongqing medicine
关键词
脑梗死
依达拉奉
纤溶酶
braini nfarction
edaravone
fibrinogenase
